Fig. 3From: Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutationsComparison of PFS between ALK-L1152R/ EGFR and non-ALK-L1152R/ EGFR on EGFR-TKI (18.2 vs 4 months, P = 0.004)Back to article page